Abbott Laboratories (ABT): Price and Financial Metrics

Abbott Laboratories (ABT)

Today's Latest Price: $106.41 USD

1.20 (-1.12%)

Updated Nov 25 7:00pm

Add ABT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ABT Stock Summary

  • ABT has a market capitalization of $188,596,995,834 -- more than approximately 99.22% of US stocks.
  • Abbott Laboratories's stock had its IPO on January 1, 1986, making it an older stock than 92.97% of US equities in our set.
  • The price/operating cash flow metric for Abbott Laboratories is higher than 85.65% of stocks in our set with a positive cash flow.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Abbott Laboratories are TMO, CSCO, PFE, NVS, and PEP.
  • ABT's SEC filings can be seen here. And to visit Abbott Laboratories's official web site, go to

ABT Stock Price Chart Interactive Chart >

Price chart for ABT

ABT Price/Volume Stats

Current price $106.41 52-week high $115.14
Prev. close $107.61 52-week low $61.61
Day low $105.63 Volume 6,224,141
Day high $108.40 Avg. volume 6,940,470
50-day MA $108.38 Dividend yield 1.35%
200-day MA $95.88 Market Cap 188.60B

Abbott Laboratories (ABT) Company Bio

Abbott Laboratories manufactures and sells health care products worldwide. The company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The company was founded in 1888 and is based in Abbott Park, Illinois.

ABT Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$106.41$34.43 -69%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Abbott Laboratories. To summarize, we found that Abbott Laboratories ranked in the 22th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Abbott Laboratories ended up being:

  • The company has produced more trailing twelve month cash flow than 90.62% of its sector Healthcare.
  • The business' balance sheet suggests that 9% of the company's capital is sourced from debt; this is greater than merely 21.78% of the free cash flow producing stocks we're observing.
  • ABT's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 38.27% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of Abbott Laboratories? See ENDP, CPIX, DHR, EHC, and RHE.

ABT Latest News Stream

Event/Time News Detail
Loading, please wait...

ABT Latest Social Stream

Loading social stream, please wait...

View Full ABT Social Stream

Latest ABT News From Around the Web

Below are the latest news stories about Abbott Laboratories that investors may wish to consider to help them evaluate ABT as an investment opportunity.

Electrophysiology Devices Market 2020-2027 Study And Future Prospects Including Key Players Abbott Laboratories, Bio sense Webster, BIOTRONIK SE & Co. KG, Etc.

The latest updated report on the Global Electrophysiology Devices Market added by Reports and Data presents a comprehensive analysis of the industry size, revenue forecast, regional spectrum of the business vertical, and further elaborates on the major hurdles, challenges, and

OpenPR | October 2, 2020

Beating COVID-19 With The Pacer BioThreat Strategy ETF (Podcast Transcript)

Editors' Note: This is the transcript of the podcast we posted last week. Please note that due to time and audio constraints, transcription may not be perfect. We encourage you to listen to the podcast, embedded below, if you need any clarification. We hope you enjoy. Sign up for Let's...

Let's Talk ETFs on Seeking Alpha | September 30, 2020

Emergency Medical Supplies Market Is Booming Worldwide | Bayer Corporation, the 3M Company, Abbott Laboratories

Emergency Medical Supplies Market - Industry Dynamics, Market Size, Opportunity And Forecast To 2026, Covid 19 Outbreak Impact research report added by Report Ocean, is an in-depth analysis of market characteristics, size and growth, segmentation, regional and country breakdowns, competitive

OpenPR | September 30, 2020

Abbott exec: Why better COVID-19 tests may help the U.S. get back to normal

As the executive running the virus surveillance program at Abbott Laboratories, one of the nation’s largest diagnostics companies, John Hackett is one busy man.

MarketWatch | September 30, 2020

Dividend Aristocrats In The Defensive Sectors

This article provides an update to the article I wrote in March: Since my March article, several changes have been made to the Dividend Aristocrats, and the stock market has mostly recovered from the crash in late February and early March. There are now 65 Dividend Aristocrats and, given growing...

FerdiS on Seeking Alpha | September 29, 2020

Read More 'ABT' Stories Here

ABT Price Returns

1-mo -0.01%
3-mo -3.63%
6-mo 12.92%
1-year 26.54%
3-year 99.74%
5-year 158.41%
YTD 24.44%
2019 22.08%
2018 29.06%
2017 52.03%
2016 -12.32%
2015 1.87%

ABT Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ABT Dividend History

Continue Researching ABT

Here are a few links from around the web to help you further your research on Abbott Laboratories's stock as an investment opportunity:

Abbott Laboratories (ABT) Stock Price | Nasdaq
Abbott Laboratories (ABT) Stock Quote, History and News - Yahoo Finance
Abbott Laboratories (ABT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9284 seconds.